US › Healthcare

Atea Pharmaceuticals Inc (AVIR)

US · Healthcare · Biotechnology

$5.26+2.14%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-32.9M

EPS

$-0.41

EPS estimate

$-0.56

EPS came in at -0.41 against a street estimate of -0.56 — a beat of 26.8%.

Key statistics

Market cap

$415.5M

Forward P/E

0.0

P/B

2.07

Book value

$2.54

EPS (TTM)

$-2.04

52-week high

$6.45

52-week low

$2.78

50-day MA

$5.06

200-day MA

$4.63

Beta

0.28

Analyst view

Analysts rate Atea Pharmaceuticals Inc a hold (1 buy, 1 hold, 1 sell out of 3) with an average price target of $9.42.

Shareholding

Insiders

13.37%

Institutions

79.06%

Largest institutional holders

Fund	Stake
FMR Inc	14.90%
BlackRock Inc	10.52%
BML Capital Management LLC	8.67%
TANG CAPITAL MANAGEMENT LLC	6.00%
Vanguard Capital Management, LLC	4.05%
Bain Capital Life Sciences Investors, LLC	2.94%
Two Sigma Investments LLC	2.32%
Geode Capital Management, LLC	2.18%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atea Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.